Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (491-500 of 584) with videos related to

Pageof 59
Sort By:
Journal of Hematology & Oncology|January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trialJorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Blood|October 9, 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoproteinAnupriya Agarwal, Ryan J Mackenzie, Arnaud Besson, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndromeGuillermo Garcia-Manero, Francesco Paolo Tambaro, Nebiyou B Bekele, et al.
Cancer|January 31, 2020
Long-term results of frontline dasatinib in chronic myeloid leukemiaAbhishek Maiti, Jorge E Cortes, Keyur P Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Cancer|August 27, 2015
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaFarhad Ravandi, Susan M O'Brien, Jorge E Cortes, et al.
The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Pageof 59

Showing results (491-500 of 584) with videos related to

Sort By:
Pageof 59
Journal of Hematology & Oncology|January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trialJorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Blood|October 9, 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoproteinAnupriya Agarwal, Ryan J Mackenzie, Arnaud Besson, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndromeGuillermo Garcia-Manero, Francesco Paolo Tambaro, Nebiyou B Bekele, et al.
Cancer|January 31, 2020
Long-term results of frontline dasatinib in chronic myeloid leukemiaAbhishek Maiti, Jorge E Cortes, Keyur P Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Cancer|August 27, 2015
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaFarhad Ravandi, Susan M O'Brien, Jorge E Cortes, et al.
The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Pageof 59